Phase I safety study of ranolazine in pulmonary arterial hypertension

Abstract. Pulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may benefit from antianginal agents based on a shared pathophysiology with left ventricular ischemia. A single-center, randomized, placebo-controlled trial (1∶1) to assess the ac...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Pulm Circ
Prif Awduron: Gomberg-Maitland, Mardi, Schilz, Robert, Mediratta, Anuj, Addetia, Karima, Coslet, Sandra, Thomeas, Vasiliki, Gillies, Hunter, Oudiz, Ronald J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: University of Chicago Press 2015
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4671743/
https://ncbi.nlm.nih.gov/pubmed/26697176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/683813
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg